ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen 2nd-Quarter Profit Rises 8.2%; 2012 Outlook Raised

By Tess Stynes Amgen Inc.'s (AMGN) second-quarter earnings rose 8.2% as weaker sales of the biopharmaceutical company's anemia drugs were offset by growth of other treatments. Shares rose 4.7% to $83 in after-hours trading Thursday as adjusted earnings and revenue beat expectations and the company raised its 2012 outlook. Through the close, the stock was up about 23% this year. For the year, the company raised its per-share earnings estimate to a range of $6.20 to $6.35 on revenue of $16.9 billion to $17.2 billion, from its prior estimates for $5.90 to $6.15 and $16.1 billion to $16.5 billion. Amgen has been pursuing deals to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed a $1.16 billion acquisition of Micromet Inc., a deal expected to strengthen its cancer-drug research pipeline. Amgen reported a profit of $1.27 billion, or $1.61 a share, up from $1.17 billion, or $1.25 a share, a year earlier. Excluding acquisition-related charges, stock-compensation expenses and other items, earnings were up at $1.83 from $1.37. Revenue increased 13% to $4.48 billion, including 8% growth in product sales. Analysts polled by Thomson Reuters most recently projected earnings of $1.54 a share on revenue of $4.08 billion. Combined sales of Neulasta and Neupogen, which are used to ward off infections in patients undergoing cancer treatment, grew 2% mainly on an increase in U.S. average selling prices. Enbrel sales jumped 11%. However, sales of anti-anemia drugs Aranesp and Epogen were down about 8% and 3%, respectively. The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Second-quarter sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, saw sales increase 17% from the first quarter. Sales of Prolia, for osteoporosis in women, climbed 36% quarter to quarter. Write to Tess Stynes at tess.stynes@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
04/25/201507:06:02Are Biosimilars the Next Big Thing in Biotech?
04/24/201516:54:55Statement of Changes in Beneficial Ownership (4)
04/24/201510:02:02Illumina's Earnings Set Positive Tone for Biotech
04/23/201517:31:15Confidential Treatment Order (ct Order)
04/23/201517:06:07Statement of Changes in Beneficial Ownership (4)
04/23/201517:02:33Nasdaq Composite Closes at Record High
04/23/201515:47:20Nasdaq Composite Rises Above March 2000 Record Close
04/23/201514:44:46AbbVie Profit Rises on Broad Sales Growth -- Update
04/23/201513:29:06Amgen, Inc. Earnings: 4 Things You Probably Overlooked
04/23/201512:03:02Is Amgen Inc.'s Dividend Sustainable?
04/23/201505:10:21Barclays Reiterates "Equal Weight" Rating for Amgen (AMGN)
04/22/201517:04:58Additional Proxy Soliciting Materials (definitive) (defa14a)
04/22/201517:00:39Additional Proxy Soliciting Materials (definitive) (defa14a)
04/22/201510:49:40Amgen Price Target Raised to $195.00 (AMGN)
04/22/201510:12:19Nomura Cuts Amgen Price Target to $191.00 (AMGN)
04/22/201504:35:02Amgen PT Raised to $187.00 at Leerink Swann (AMGN)
04/22/201503:41:08RBC Capital Raises Amgen Price Target to $185.00 (AMGN)
04/21/201517:14:12Amgen Reports Higher Earnings, Outlook -- Update
04/21/201516:50:10Amgen Posts 51% Rise in Profit, Boosts Outlook
04/21/201516:35:18Amgen Posts 51% Rise in Profit, Boosts 2015 Outlook

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad